Adaptive Phage Therapeutics to collaborate with Yale’s Paul Turner Lab

Adaptive Phage Therapeutics Enters into Collaboration Agreement with Researchers at Yale University to Manufacture and Supply Therapeutic Bacteriophage. View this release on BusinessWire   Gaithersburg, Maryland, December 12, 2018 - Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced it has entered into a collaboration agreement with the Paul Turner Lab at Yale University to manufacture and supply therapeutic bacteriophage (phage) for use in clinical trials. Through this collaboration, APT is committed to leveraging the exquisite specificity and potency of phage in the fight against the global rise of MDR infections. Under the terms of the agreement, APT will manufacture therapeutic phage in their state-of-the-art facilities under the Food and Drug Administration (FDA) Good Manufacturing Practice conditions. APT has the only facility specifically designed and focused on the rapid and precise delivery of phage therapy. The facility includes a first of its kind robotic aseptic filling system, separate phage amplification and purification labs, and automated companion diagnostic systems capability of rapid matching of a patient's bacteria to the world's largest collection of therapeutic phage (PhageBank(TM)).   "APT is thrilled to partner with the Paul Turner Lab to support their pioneering phage therapy initiatives, which have the promise to help combat the growing antibiotic resistance crisis," said Greg Merril, chief executive officer and co-founder of APT.